As per MRFR analysis, the US Structural Heart Devices Market Size was estimated at 173.95 (USD Million) in 2023. The US Structural Heart Devices Market Industry is expected to grow from 191.5(USD Million) in 2024 to 409.5 (USD Million) by 2035. The US Structural Heart Devices Market CAGR (growth rate) is expected to be around 7.154% during the forecast period (2025 - 2035).
The US Structural Heart Devices Market is witnessing significant trends driven by several factors. One important market driver is the increasing prevalence of structural heart disorders, such as valve diseases and congenital heart defects, leading to greater demand for innovative treatment solutions. The aging population in the US also plays a critical role, as older individuals are more susceptible to these conditions, prompting healthcare providers to seek effective interventions. Additionally, technological advancements in device manufacturing and minimally invasive procedures are enhancing patient outcomes, thus encouraging adoption among healthcare professionals and patients alike.
Opportunities in the US market are expanding with the growing focus on personalized medicine and enhanced patient-centered care. Companies specializing in structural heart devices are exploring partnerships with healthcare institutions to develop tailored solutions that cater to individual patient needs. This shift towards customized treatments is opening new avenues for innovation and market entry. Furthermore, an increase in clinical trials and regulatory approvals for new devices indicates a robust pipeline of upcoming products that could transform the treatment landscape for structural heart diseases.
Recently, trends in the US have also leaned towards an emphasis on remote patient monitoring and digital health solutions.The rise of telehealth, especially during the pandemic, has prompted the integration of digital technologies with structural heart devices, enabling continuous monitoring and better patient management. The growing acceptance of these technologies by both patients and healthcare providers marks a significant shift in how structural heart diseases are being treated and monitored, making the market dynamic and evolving. As these trends continue to develop, they are likely to shape the future of the Structural Heart Devices Market in the US, influencing both product development and delivery of care.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The prevalence of heart diseases in the United States continues to rise, contributing significantly to growth in the US Structural Heart Devices Market Industry. According to the Centers for Disease Control and Prevention (CDC), about 696,000 Americans die from heart disease each year, making it the leading cause of death in the country. This alarming statistic reflects a critical need for innovative structural heart devices that can offer effective treatment options.
The American Heart Association has also reported a steady increase in heart failure cases, projecting that the number of people living with heart failure could rise to 8 million by 2030. This growing demographic creates substantial market opportunities for manufacturers and innovators in the structural heart devices field. Leading organizations such as Medtronic and Abbott have been actively advancing their portfolios to cater to this increasing demand, indicating a robust commitment to Research and Development in response to this pressing healthcare need.
The US Structural Heart Devices Market Industry is significantly benefitting from rapid technological advancements in medical device manufacturing. The innovation of minimally invasive devices and enhanced imaging techniques have transformed surgical procedures. For example, transcatheter aortic valve replacement (TAVR) procedures have grown substantially, with the Society for Cardiovascular Angiography and Interventions noting a 24% increase in TAVR procedures performed in hospitals across the US.
These advancements not only improve patient outcomes by reducing recovery times and hospital stays but also attract healthcare providers towards newer technologies. Companies like Edwards Lifesciences are at the forefront of these innovations, continuously developing devices that integrate advanced materials and designs, contributing to the overall growth and efficacy of the US Structural Heart Devices Market.
The aging population in the United States is poised to drive significant growth in the US Structural Heart Devices Market Industry. According to the Administration for Community Living, the number of individuals aged 65 and older is expected to double from 52 million in 2018 to more than 95 million by 2060. This demographic shift leads to increased incidences of age-related illnesses, including heart valve diseases, pushing the demand for structural heart devices.
This trend encourages healthcare providers and device manufacturers to focus on products tailored for elderly patients, enhancing treatment efficacy and safety. Companies like Boston Scientific are aligning their product strategies to address the specific needs of this growing patient segment, further propelling market growth and technological advancements.
The US Structural Heart Devices Market, categorized by Type, showcases a progressive landscape that is essential for addressing various cardiovascular conditions affecting patients across the region. The Heart Valve Devices segment plays a critical role in this market, as it is specifically designed for the treatment of valvular heart diseases, which are prevalent among the aging population in the United States. With a growing emphasis on minimizing risks associated with surgeries, these devices often adopt less invasive techniques, thus driving their acceptance and adoption among medical professionals.
Meanwhile, Annuloplasty Rings are instrumental in supporting effective mitral and tricuspid valve repair procedures. They possess a significant impact on enhancing post-surgical recovery outcomes, thereby contributing positively to the overall operational efficiency within hospitals. Occluders are another vital component of the Type classification, primarily addressing issues related to congenital heart defects. By efficiently sealing abnormal holes in the heart, these devices decrease complications and improve the quality of life for affected patients.
Their increasingly favorable acceptance stems from advancements in device technology and better patient outcomes, which are important metrics for healthcare providers. Additionally, Delivery Systems ensure the accurate placement of these cardiac devices within the heart, which is crucial for ensuring effectiveness. As technology evolves, the precision and reliability of Delivery Systems have notably improved, allowing for more successful procedures and better patient satisfaction.
Throughout the industry, the focus on enhancing patient outcomes, paired with an increasing prevalence of cardiovascular diseases, are strong growth drivers for all Types of devices within the US Structural Heart Devices Market. Furthermore, the rising trend of minimally invasive surgeries is pushing innovation in device designs and delivery methods, as healthcare providers strive for safer and more efficient solutions. Challenges remain, including regulatory hurdles and the need for substantial Research and Development investments before new devices can reach the market, but the overall opportunities for growth within this segment are significant. The increasing demand for heart-related interventions presents a favorable environment for manufacturers and healthcare providers alike, fostering advancements that align with the ongoing evolution of cardiovascular care in the United States.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Structural Heart Devices Market is significantly influenced by the indication segment, where conditions such as Valvular Heart Disease and Cardiomyopathy play crucial roles. Valvular Heart Disease often necessitates intervention through devices such as transcatheter aortic valves or repair devices, addressing a critical need for many patients suffering from debilitating symptoms. Cardiomyopathy, on the other hand, represents a diverse range of heart muscle diseases, also driving the adoption of structural heart devices to improve quality of life and manage symptoms effectively.
The rising prevalence of these conditions in the US, and the increasing awareness of available treatment options, support robust growth within this market. Technological advancements in device design and implementation further enhance procedural success rates, thereby contributing to the positive outlook of the US Structural Heart Devices Market industry. Furthermore, the aging population in the US, which is more susceptible to heart diseases, presents ample opportunities for market expansion and advancements in this therapeutic area. Overall, the attention given to these indications underscores the importance of structural heart interventions in contemporary cardiovascular care.
The US Structural Heart Devices Market is experiencing significant advancements within the Procedure segment, particularly highlighted by the growing focus on Replacement Procedures and Repair Procedures. Replacement Procedures are crucial as they address severe heart valve diseases, providing life-saving options for patients who may otherwise face severe health risks. On the other hand, Repair Procedures have gained favor due to their less invasive nature, often resulting in quicker recovery times and fewer complications.
These procedures play a vital role in managing conditions such as valve stenosis and regurgitation, showcasing the importance of intervention in preventing further cardiovascular complications. The rising incidence of heart diseases in the US is driving the demand within this segment, with healthcare professionals increasingly emphasizing the benefits of early intervention. Moreover, technological advancements and innovation within the US medical device industry are further enhancing the effectiveness of these procedures. As a result, the Procedure segment is poised to play a significant role in transforming patient outcomes and driving procedural volume in the years to come, indicating a promising trajectory for the US Structural Heart Devices Market.
The US Structural Heart Devices Market has become a crucial area within the broader cardiovascular sphere, primarily driven by the increasing prevalence of heart diseases and the population's aging demographic. Technological innovations, a rise in minimally invasive procedures, and heightened awareness of heart health are propelling this market into a competitive landscape characterized by rapid advancements and strategic collaborations. Companies operating in this segment focus on enhancing procedural efficiencies and improving patient outcomes, leading to an influx of novel devices that cater to various structural heart conditions. Market players continually seek to strengthen their foothold by investing in research and development, aligning with healthcare providers, and exploring new therapeutic avenues, all of which underline the importance of competitive insights in navigating this dynamic sector.
LivaNova stands out in the US Structural Heart Devices Market due to its commitment to advancing patient care through innovative devices and therapies. The company’s focus on providing cutting-edge products, along with a strong emphasis on research, plays a significant role in its sustained market presence. LivaNova has successfully developed technologies that address various structural heart-related ailments, thereby enhancing treatment options for healthcare providers. The integration of clinical data and patient feedback into the product development cycle allows LivaNova to retain a competitive edge, ensuring their offerings are aligned with real-world needs. The company’s robust partnerships and collaborations with hospitals and cardiovascular specialists in the US reinforce its commitment to improve procedural success and are pivotal in bolstering its reputation within the marketplace.
AtriCure operates with a distinctive approach in the US Structural Heart Devices Market, primarily focusing on innovative solutions for atrial fibrillation and other structural heart conditions. The company offers a range of products, particularly in ablation technologies that target the correction of irregular heartbeats associated with various structural heart diseases. AtriCure has made notable advancements in its product portfolio, emphasizing minimally invasive techniques that allow for improved recovery times and reduced patient risk. Their strategic mergers and acquisitions have enabled AtriCure to broaden its technological capabilities and expand its market share. By leveraging these strengths, the company has established a solid foundation in the US market, consistently prioritizing research and enhancing collaborations with healthcare providers to drive forward the development of advanced therapies. The synergy from these efforts continues to bolster AtriCure’s position in the competitive landscape, offering innovative solutions that cater specifically to the evolving needs of patients and healthcare systems.
Recent developments in the US Structural Heart Devices Market have included significant advancements and investments as companies focus on innovative therapies. Notably, Medtronic has gained attention with its ongoing investment in the HeartWare product line designed for heart failure treatments. Abbott Laboratories continues to expand the adoption of its MitraClip device, which has shown substantial success in treating mitral valve regurgitation. In September 2023, Boston Scientific made headlines with a strategic partnership aimed at enhancing its structural heart portfolio, further solidifying its place in the market.
Acquisitions have also been influential in the market landscape, such as Edwards Lifesciences acquiring a technology firm in June 2023 to accelerate its Research and Development efforts for transcatheter heart valves. Additionally, in the same month, LivaNova announced its merger with a leading cardiovascular technology organization, strengthening its market position and enhancing its product offerings. The growth in market valuations among key players reflects an overall expanding interest in structural heart therapies, with the total market value anticipated to surpass USD 12 billion by 2025 as more patients are diagnosed and treated, emphasizing the importance of alliances and innovation in this sector.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 173.95(USD Million) |
| MARKET SIZE 2024 | 191.5(USD Million) |
| MARKET SIZE 2035 | 409.5(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.154% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | LivaNova, AtriCure, MitraClip, Nuvectra, Cardiac Dimensions, SentreHEART, Terumo Corporation, HeartWare, Medtronic, Abbott Laboratories, Boston Scientific, Edwards Lifesciences, Tendyne, CryoLife, Johnson and Johnson |
| SEGMENTS COVERED | Type, Indication, Procedure |
| KEY MARKET OPPORTUNITIES | Aging population prevalence, Innovative minimally invasive techniques, Technological advancements in devices, Increasing cardiovascular disease rates, Expanding reimbursement policies for procedures |
| KEY MARKET DYNAMICS | Aging population, Rising incidence of heart disease, Technological advancements, Increasing demand for minimally invasive procedures, Favorable reimbursement policies |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Structural Heart Devices Market is expected to be valued at 191.5 million USD in 2024.
By 2035, the market is anticipated to reach approximately 409.5 million USD.
The expected CAGR for the US Structural Heart Devices Market from 2025 to 2035 is 7.154 percent.
In 2024, Heart Valve Devices account for the largest share at 80.0 million USD.
The market for Annuloplasty Rings is projected to increase to 60.0 million USD by 2035.
Major players in the market include Medtronic, Abbott Laboratories, and Boston Scientific.
Occluders are expected to show substantial growth, increasing from 45.0 million USD in 2024 to 90.0 million USD in 2035.
Challenges include regulatory hurdles and the need for continued innovations to meet demand.
Opportunities include expanding technologies and growing awareness of heart health solutions.
Technological advancements are anticipated to drive market growth and enhance patient outcomes significantly.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
